Healthcare

According to a market report by Lucintel, the future of the vaccine adjuvant market looks promising with opportunities in infectious disease and cancer applications. The global vaccine adjuvant market. The global vaccine adjuvant market is expected to reach an estimated $2.6 billion by 2028 with a CAGR of 12.6% from 2023 to 2028. The major drivers for this market are increasing prevalence of infectious diseases and increasing government initiatives and funding for vaccine research and development.



In this market, pathogen, adjuvant emulsion, particulate, and combination are the major product segments. Lucintel forecast that adjuvant emulsion will remain the largest product segment over the forecast period due to growing number of adjuvanted vaccines across the globe. 



Within this market, infectious disease segment is projected to witness the highest growth due to growing prevalence of infectious diseases, such as malaria, influenza, and hepatitis A, B, & C and increasing government initiatives to support vaccine development.



The North American region is expected to witness the highest growth during the forecast period due to increasing investment for the development of veterinary healthcare infrastructure and growing government initiatives towards immunization programs.

GlaxoSmithKline, Novavax, SPI Pharma, Agenus, CSL Limited, InvivoGen, and Brenntag Biosector are the major suppliers in the global vaccine adjuvant market.  



Lucintel, a leading global strategic consulting and market research firm, has analysed growth opportunities in the global product, application, and region. Lucintel has compiled a comprehensive research report entitled “Growth Opportunities in the Global Vaccine Adjuvant Market 2023-2028: Trends, Forecast, and Opportunity Analysis.” The Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global vaccine adjuvant market by product, application, and region, as follows:

 

This more than 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or email us at helpdesk@lucintel.com.

 

Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. Lucintel offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

 

Q.1. What are some of the most promising, high-growth opportunities for the vaccine adjuvant market by product (pathogen, adjuvant emulsion, particulate, and combination), application (infectious disease and cancer), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last five years and what has its impact been on the industry?